| Literature DB >> 32062751 |
Dong Wang1, Redouane Tabti2, Sabria Elderwish2, Hussein Abou-Hamdan2, Amel Djehal2,3, Peng Yu1, Hajime Yurugi4, Krishnaraj Rajalingam4, Canan G Nebigil2, Laurent Désaubry5,6.
Abstract
Over the last three decades, the scaffold proteins prohibitins-1 and -2 (PHB1/2) have emerged as key signaling proteins regulating a myriad of signaling pathways in health and diseases. Small molecules targeting PHBs display promising effects against cancers, osteoporosis, inflammatory, cardiac and neurodegenerative diseases. This review provides an updated overview of the various classes of PHB ligands, with an emphasis on their mechanism of action and therapeutic potential. We also describe how these ligands have been used to explore PHB signaling in different physiological and pathological settings.Entities:
Keywords: Alzheimer disease; Autoimmune disease; C-RAF; Cancer; Cardiac diseases; Cardio-oncology; Cell signaling; Drug discovery; Inflammation; KRAS; LC3; MAP kinase; Melanogenesis; Mitophagy; NF-kB; Osteoclastogenesis; Osteoporosis; Parkinson disease; RAF1; Scaffold proteins; Wnt
Mesh:
Substances:
Year: 2020 PMID: 32062751 DOI: 10.1007/s00018-020-03475-1
Source DB: PubMed Journal: Cell Mol Life Sci ISSN: 1420-682X Impact factor: 9.261